本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
NEW YORK, May 17, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its unaudited financial results for the first quarter ended March 31, 2023. The Company's financial statements and related financial information for the quarter ended March 31, 2023 are unaudited and have not been reviewed by the Company's independent registered accountant. These financial results could differ materially if they were reviewed by the Company's independent registered accountant. Financial Highlights for First Quarter 2023 Total revenue was approximately RMB593,000 (US$87,000) for the first quarter of 2023, a decrease of 69.9% from approximately RMB2.0 million for the same period of 2022. Gross profit margin was 25.0% for the first quarter of 2023, representing a decrease of 30.4 percentage point from 55.4% for the same period of 2022. The average selling price ("ASP") of CDA-based tests was RMB330 (US$48.1) for the first quarter of 2023, an increase of RMB97.0, or 41.6% from RMB233 for the same period of 2022. Net loss was approximately RMB23.3 million (US$3.4 million) for the first quarter of 2023, compared to a net loss of approximately RMB14.9 million for the same period of 2022, a 56.6% increase from the same period in 2022. The net loss for the first quarter of 2023 was mainly attributable to approximately RMB2.4 million (US$354,000) of selling and marketing expenses, approximately RMB1.6 million (US$228,000) of research and development expenses and approximately RMB19.5 million (US$2.8 million) of general and administrative expenses. Non-GAAP net loss[1] was approximately RMB22.3 million (US$3.2 million) for the first quarter of 2023, an increase from a non-GAAP net loss of approximately RMB12.1 million for the same period of 2022. Non-GAAP net loss was increased by 84.2% compared with the same period of 2022 [1] Non-GAAP net loss is defined as net loss excluding change in fair value of convertible debts and share-based compensation. For more information, refer to "Use of Non-GAAP Financial Measures" and "Reconciliations of Non-GAAP Results" at the end of this report. Business Highlights First Quarter 2023 The Company continued to receive validation on the efficacy of CDA testing through clinical study follow-ups. As of March 31, 2023, the Company had contacted 31,367 individuals tested using CDA packages in China and received substantive feedback regarding health conditions and disease development from 18,306 individuals. As of March 31, 2023, the Company filed 260 patent applications globally, of which 155 patents had been granted, including 22 patents granted in the United States, 68 in greater China (including eight in Taiwan), and 65 in other countries and regions. The Company continued to build a cancer risk assessment database, which totaled approximately 286,472 samples as of March 31, 2023, including approximately 241,541 samples from commercial CDA-based tests and approximately 44,931 samples from research studies. As of March 31, 2023, the Company has entered a new business segment, the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, in line with our strategic growth plan. During the quarter ended March 31, 2023, the Company closed three acquisitions aimed at enhancing our operational efficiency in the new business segment, expanding our product/service offerings, and strengthening our competitive position in the e-commerce industry. Mr. Haohan Xu, the Co-CEO of the Company, commented, "We have been actively exploring new business opportunities to diversify our revenue stream, despite the unfavorable macro environment for our existing biotech business. Currently, we are striving to build a leading e-commerce platform in the U.S. that offers online wholesale food supplies for restaurants and supermarkets. We are committed to helping restaurants and supermarkets reduce procurement costs and increase efficiency by utilizing an intelligent supply chain management system. We will allow our customers to directly connect with reliable suppliers, ensuring that the food purchased is consistent in quality with competitive prices, and the source of the food can be determined. We have opened our platform to multiple categories of suppliers, while also providing a comprehensive supply chain service. By leveraging digital technology and innovative business models, we intend to drive the online transformation of the food supply industry. We believe our growth strategy positions us well to develop a customer base, generate a steady revenue stream, and improve our profitability in the long run. Looking forward, we will continue to focus on implementing our growth strategies and invest in our business to capture the massive opportunities we see in the U.S. market." Financial Results for First Quarter 2023 Revenue Total revenues decreased by 69.9% to approximately RMB593,000 (US$87,000) for the first quarter of 2023 from approximately RMB2.0 million for the first quarter of 2022, primarily due to a significant decrease in our revenue from cancer screening and detection tests. Cost of Revenues Cost of revenues decreased by 49.3% to approximately RMB445,000 (US$65,000) for the first quarter of 2023 from approximately RMB878,000 for the first quarter of 2023, which was in line with the decrease in our revenue. Gross Profit and Gross Margin Gross margin was 25.0% for the first quarter of 2023, representing a decrease from 55.4% for the first quarter of 2022, primarily due to fixed costs which did not change in line with the decrease in our revenue. Selling and Marketing Expenses Selling and marketing expenses decreased by 17.0% to approximately RMB2.4 million (US$354,000) for the first quarter of 2023 from approximately RMB2.9 million for the same period of 2022, primarily due to less marketing activity. Research and Development Expenses Research and development expenses decreased by 34.8% to approximately RMB1.6 million (US$228,000) for the first quarter of 2023 from approximately RMB2.4 million for the first quarter of 2022, primarily due to less research and development activities for the first quarter of 2023 compared to the same period of 2022. General and Administrative Expenses General and administrative expenses increased by 89.4% to approximately RMB19.5 million (US$2.8 million) for the first quarter of 2023 from approximately RMB10.3 million for the same period of 2022, primarily due to increase expenses related to our new business. Net Loss Net loss decreased to approximately RMB23.3 million (US$3.4 million) for the first quarter of 2023, compared to approximately RMB14.9 million for the first quarter of 2022. Basic and diluted loss per share was RMB0.31 (US$0.04) for the first quarter of 2023 compared to that of RMB0.85 for the first quarter of 2022. About Fresh2 Group Limited Fresh2 Group Limited is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2023. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, Fresh2 performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. The Company is entering the business-to-business e-commerce food business with the formation of its wholly-owned subsidiary Fresh2 Technology Inc and the acquisition of Fresh2 Ecommerce Inc. For more information, please visit: https://fresh2.co/investors. For investor and media inquiries, please contact: Ascent Investor Relations LLCTina XiaoPhone: +1-917-609-0333 (U.S.)Email: tina.xiao@ascent-ir.com Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules including maintain our listing on the Nasdaq Capital Market, the implementation of our business model and growth strategies including our operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. A number of these risks along with additional discussion of forward-looking statements, are set forth in the Company's Annual Report on Form 20-F and other reports filed with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the COVID19 virus and the impact it will have on the Company's operations, global supply chains and economic activity in general. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason. FRESH2 GROUP LIMITED (FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.) UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$"), except for number of shares and per share data) As of December 31, As of March 31, 2022 2023 2023 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 1,870 2,521 367 Prepayment 3,742 12,760 1,858 Accounts receivable, net 2,235 3,215 468 Amounts due from related parties, net 2,194 13,122 1,911 Inventories, net 210 197 29 Other current assets, net 3,448 6,240 909 Total current assets 13,699 38,055 5,542 Property and equipment, net 17,182 19,395 2,824 Land use rights, net 1,111 1,104 161 Intangible assets, net 185 68,574 9,985 Goodwill — 17,299 2,519 Right of use assets 7,213 7,233 1,053 Long-term investments, net 1,079 1,068 156 TOTAL ASSETS. 40,469 152,728 22,240 LIABILITIES AND SHAREHOLDERS' DEFICIT Current liabilities: Short-term debts 5,015 5,015 730 Accounts payable 2,108 14,569 2,122 Advance from customers 4,956 5,633 820 Amounts due to related parties 3,494 7,090 1,032 Lease liability-current 784 795 116 Accrued expenses and other current liabilities 25,921 30,793 4,484 Total current liabilities 42,278 63,895 9,304 Deferred tax liabilities — 2,813 410 Lease liability-non-current 6,515 6,523 950 Other long-term liabilities 1,080 1,073 156 TOTAL LIABILITIES. 49,873 74,304 10,820 Commitments and contingencies Shareholders' equity (deficit): Class A Ordinary shares ((US$0.01 par value per share; 2,400,000,000 shares authorized, 79,536,589 and 136,625,576 shares issued and outstanding as of December 31, 2022 and March 31, 2023, respectively) 5,494 8,466 1,233 Class B Ordinary shares ((US$0.01 par value per share; 30,000,000 authorized, 3,573,100 and 3,573,100 shares issued and outstanding as of December 31, 2022 and March 31, 2023) 240 240 35 Treasury stocks (12,492,283 shares Class A Ordinary shares) (11,003) — — Additional paid-in capital 564,869 660,559 96,185 Accumulated deficit (577,539) (600,536) (87,445) Accumulated other comprehensive income 4,263 5,756 838 Total Fresh2 Group Limited shareholders' equity (deficit) (13,676) 74,485 10,846 Non-controlling interest 4,272 3,939 574 Total shareholders' equity (deficit) (9,404) 78,424 11,420 TOTAL LIABILITIES AND EQUITY 40,469 152,728 22,240 FRESH2 GROUP LIMITED (FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.) UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$"), except for number of shares and per share data) Three Months Ended March 31, 2022 2023 2023 RMB RMB US$ Revenues: Cancer screening and detection tests 1,137 588 86 Physical checkup packages 5 5 1 Technology service 620 — — Retail revenue 206 — — Total revenues 1,968 593 87 Cost of revenues (878) (445) (65) Gross Profit 1,090 148 22 Operating expenses: Selling and marketing expenses (2,932) (2,434) (354) Research and development expenses (2,407) (1,570) (228) General and administrative expenses (10,287) (19,483) (2,837) Loss from operations (14,536) (23,339) (3,397) Non-operating income and expenses: Interest expense, net (93) (34) (5) Foreign exchange gain (loss), net 2 (6) (1) Share of net loss in equity method investments (181) (11) (2) Other income (expense), net (97) 12 2 Change in fair value of convertible debt (85) — — Loss before income taxes (14,990) (23,378) (3,403) Income tax benefit 90 48 7 Net loss (14,900) (23,330) (3,396) Net loss attributable to non-controlling interests (261) (333) (48) Net loss attributable to ordinary shareholders (14,639) (22,997) (3,348) Loss per share: Class A and B Ordinary shares - basic and diluted (0.85) (0.31) (0.04) Weighted average shares outstanding used in calculating basic and diluted loss per share Ordinary shares - basic and diluted 17,301,503 74,452,222 74,452,222 Other comprehensive income, net of tax: Foreign currency translation differences 376 1,493 217 Total comprehensive loss (14,524) (21,837) (3,179) Total comprehensive loss attributable to non-controlling interests (261) (333) (48) Total comprehensive loss attributable to ordinary shareholders (14,263) (21,504) (3,131) Use of Non-GAAP Financial Measures Non-GAAP net loss is calculated as net income adjusted for change in fair value of convertible debts and stock-based compensation expense. The non-GAAP financial measures are presented to enhance investors' overall understanding of the Company's financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. Investors are encouraged to review the reconciliation of the historical non-GAAP financial measures to its most directly comparable GAAP financial measures. As non-GAAP financial measures have material limitations as analytical metrics and may not be calculated in the same manner by all companies, they may not be comparable to other similarly titled measures used by other companies. In light of the foregoing limitations, you should not consider non-GAAP financial measures as a substitute for, or superior to, such metrics in accordance with US GAAP. Reconciliations of Non-GAAP Results Reconciliations of Non-GAAP net loss (All amounts in thousands, except share and per share data or otherwise stated) Three Months Ended March 31, March 31, March 31, March 31, 2022 2023 2023 RMB RMB US$ Net loss (14,900) (23,330) (3,396) Less: Change in fair value of convertible debts 85 — — Stock based compensation expense 2,703 1,018 148 Non-GAAP net loss (12,112) (22,312) (3,248)
NEW YORK, May 17, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021. Gross margin was 69.2% in the year ended December 31, 2022, an increase of 1.1 percentage point from 68.1% in the year ended December 31, 2021. The average selling price ("ASP") of CDA-based tests was RMB266 (US$39) in the year ended December 31, 2022, a decrease of RMB121, or 31.3% from RMB387 in the year ended December 31, 2021, primarily due to that more customers only performed basic CDA test with lower pricing instead of comprehensive combined CDA test. Net loss decreased to RMB103.6 million (US$15.0 million) in the year ended December 31, 2022 from RMB120.1 million in the year ended December 31, 2021, mainly attributable to the decrease of approximately RMB9.3 million in selling and marketing expenses, the decrease of approximately RMB6.7 million in research and development expenses, and the decrease of approximately RMB9.9 million in general and administrative expenses, offset by approximately $14.7 million decrease in impairment of intangible assets and goodwill. Non-GAAP net loss(1) was approximately RMB88.8 million (US$12.9 million) in the year ended December 31, 2022, an increase from a non-GAAP net loss of approximately RMB76.8 million in the year ended December 31, 2021. Non-GAAP net loss increased by 15.6% from the year ended December 31, 2021. Short-term debt decreased significantly (a decrease of approximately 85.1%) compared to December 31, 2021, because the conversion of Convertible Debentures into ordinary shares. (1) Non-GAAP net loss is defined as net loss excluding change in fair value of convertible debts and share-based compensation. For more information, refer to "Use of Non-GAAP Financial Measures" and "Reconciliations of Non-GAAP Results" at the end of this report. Business Highlights Fiscal Year 2022 The Company continued to receive validation on the efficacy of CDA testing through clinical study follow-ups. As of December 31, 2022, the Company had contacted 30,526 individuals tested using CDA packages in China and received substantive feedback regarding health conditions and disease development from 17,824 individuals. As of December 31, 2022, the Company filed 260 patent applications globally, among which 155 patents had been granted, including 22 patents granted in the United States, 68 in greater China (including eight in Taiwan), and 65 in other countries and regions. The Company continued to build a cancer risk assessment database, which totaled approximately 280,095 samples as of December 31, 2022, including approximately 239759 samples from commercial CDA-based tests and approximately 44,653 samples from research studies. Mr. Haohan Xu, the Co-CEO of the Company, commented "Despite facing tremendous challenges in the market, we have made progress in several areas during the year ended December 31, 2022. For instance, we achieved an increase in our gross margin, reflecting our focus on cost management and operational efficiency. While acknowledging the challenges in our existing biotech business, we have been actively exploring new business opportunities targeting restaurants and supermarkets, as mentioned in our recent press releases. Specifically, we acquired Fresh2 Ecommerce Inc, a business-to-business e-commerce platform focused on connecting Asian food suppliers and supermarkets in the U.S. to enter into the U.S. food market by initiating and developing a new e-commerce platform. We also acquired certain fixed assets of Easy Hundred Inc., a U.S.-based e-commerce company in the foodservice industry, and its intellectual property to optimize our industry supply chain and supplement the acquired Fresh2 Ecommerce Inc.'s business-to-business e-commerce platform. In addition, we acquired GISN (HK) LIMITED, a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises to improve the efficiency of our e-commerce operations. We believe that these acquisitions will diversify our revenue streams, help to fill financial gaps, drive growth for the Company, and ultimately create long term value for our shareholders." About Fresh2 Group Limited Fresh2 Group Limited is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2023. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, Fresh2 performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. The Company is entering the business-to-business e-commerce food business with the formation of its wholly-owned subsidiary Fresh2 Technology Inc and the acquisition of Fresh2 Ecommerce Inc. For more information, please visit: https://fresh2.co/investors. For investor and media inquiries, please contact: Ascent Investor Relations LLCTina XiaoPhone: +1-917-609-0333 (U.S.)Email: tina.xiao@ascent-ir.com Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. The Company has attempted to identify forward-looking statements by terminologies including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "target," "aim," "predict," "outlook," "seek," "goal" "objective," "assume," "contemplate," "continue," "positioned," "forecast," "likely," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to comply with Nasdaq Listing Rules including maintain our listing on the Nasdaq Capital Market, the implementation of our business model and growth strategies; trends and competition in the cancer screening and detection market; our expectations regarding demand for and market acceptance of our cancer screening and detection tests and our ability to expand our customer base; our ability to obtain and maintain intellectual property protections for our CDA technology and our continued research and development to keep pace with technology developments; our ability to obtain and maintain regulatory approvals from the NMPA, the FDA and the relevant U.S. states and have our laboratories certified or accredited by authorities including the CLIA; our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; general economic and business conditions in China and elsewhere; our ability to hire and maintain key personnel; our relationship with our major business partners and customers; and the duration of the coronavirus outbreaks and their potential adverse impact on the economic conditions and financial markets and our business and financial performance, such as resulting from reduced commercial activities due to quarantines and travel restrictions instituted by China, the U.S. and many other countries around the world to contain the spread of the virus. A number of these risks along with additional discussion of forward-looking statements, are set forth in the Company's Annual Report on Form 20-F and other reports filed with the Securities and Exchange Commission. In addition, there is uncertainty about the spread of the COVID19 virus and the impact it will have on the Company's operations, global supply chains and economic activity in general. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason. FRESH2 GROUP LIMITED (FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.) CONSOLIDATED BALANCE SHEETS (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$"), except for number of shares and per share data) As of December 31, 2021 2022 2022 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 9,251 1,870 271 Advances to suppliers 4,704 3,742 543 Accounts receivable, net 5,554 2,235 324 Amounts due from related parties, net 200 2,194 318 Inventories, net 490 210 30 Other current assets, net 3,350 3,448 500 Total current assets 23,549 13,699 1,986 Property and equipment, net 20,264 17,182 2,491 Land use rights, net 1,138 1,111 161 Intangible assets, net 8,857 185 27 Goodwill 12,758 — — Right of use assets — 7,213 1,046 Long-term investments, net 923 1,079 156 TOTAL ASSETS. 67,489 40,469 5,867 LIABILITIES AND SHAREHOLDERS' DEFICIT Current liabilities: Short-term debts 33,759 5,015 727 Accounts payable 2,732 2,108 303 Advance from customers 4,174 4,956 719 Amounts due to related parties 2,471 3,494 507 Lease liability-current — 784 114 Accrued expenses and other current liabilities 19,770 25,921 3,758 Total current liabilities 62,906 42,278 6,128 Deferred tax liabilities 2,158 — — Lease liability-non-current — 6,515 945 Other long-term liabilities 1,107 1,080 157 TOTAL LIABILITIES. 66,171 49,873 7,230 Commitments and contingencies Shareholders' equity (deficit):: Class A Ordinary shares ((US$0.01 par value per share; 2,400,000,000 shares authorized, 16,604,402 and 79,536,589 shares issued and 16,604,402 and 67,044,306 outstanding as of December 31, 2021 and 2022, respectively) 1,096 5,494 797 Class B Ordinary shares ((US$0.01 par value per share; 30,000,000 authorized, 2,773,100 and 3,573,100 shares issued and outstanding as of December 31, 2021 and 2022) 185 240 35 Treasure stocks(1) — (11,003) (1,595) Additional paid-in capital 465,334 564,869 81,898 Accumulated deficit (475,646) (577,539) (83,735) Accumulated other comprehensive income 4,532 4,263 618 Total Fresh2 Group Limited shareholders' deficit (4,499) (13,676) (1,982) Non-controlling interest 5,817 4,272 619 Total shareholders' equity (deficit) 1,318 (9,404) (1,363) TOTAL LIABILITIES AND EQUITY (DEFICIT) 67,489 40,469 5,867 (1): 12,492,283 shares Class A Ordinary shares were held as treasury stock. FRESH2 GROUP LIMITED (FORMERLY ANPAC BIO-MEDICAL SCIENCE CO., LTD.) CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Amounts in thousands of Renminbi ("RMB") and U.S. dollars ("US$"), except for number of shares and per share data) For the years ended December 31, 2021 2022 2022 RMB RMB US$ Revenues: Cancer screening and detection tests 14,947 8,078 1,171 Physical checkup packages 1,654 1,574 228 Technology service 1,284 2,186 317 Retail revenue 101 206 30 Total revenues 17,986 12,044 1,746 Cost of revenues (5,732) (3,708) (538) Gross Profit 12,254 8,336 1,208 Operating expenses: Selling and marketing expenses (21,420) (12,154) (1,762) Research and development expenses (16,204) (9,532) (1,381) General and administrative expenses (80,676) (70,788) (10,263) Impairment intangible assets (3,828) (7,911) (1,147) Impairment of goodwill (2,223) (12,758) (1,850) Loss from operations (112,097) (104,807) (15,195) Non-operating income and expenses: Interest expense, net (4,257) (373) (54) Foreign exchange loss, net (202) (787) (114) Share of net gain in equity method investments 132 156 23 Other income, net 990 (61) (9) Change in fair value of convertible debt (9,073) 144 21 Gain from fair value change in equity investment 3,240 — — Loss before income taxes (121,267) (105,728) (15,328) Income tax benefit 1,180 2,130 309 Net loss (120,087) (103,598) (15,019) Net loss attributable to non-controlling interests (1,392) (1,705) (247) Net loss attributable to ordinary shareholders (118,695) (101,893) (14,772) Loss per share: Class A and B Ordinary shares – basic and diluted (8.72) (2.66) (0.39) Weighted average shares outstanding used in calculating basic and diluted loss per share 13,605,515 38,242,073 38,242,073 Ordinary shares - basic and diluted Other comprehensive loss, net of tax: Foreign currency translation differences (263) (269) (39) Total comprehensive loss (120,350) (103,867) (15,058) Total comprehensive loss attributable to non-controlling interests (1,392) (1,705) (247) Total comprehensive loss attributable to ordinary shareholders (118,958) (102,162) (14,811) Use of Non-GAAP Financial Measures Non-GAAP net loss is calculated as net income adjusted for change in fair value of convertible debts and stock-based compensation expense. The non-GAAP financial measures are presented to enhance investors' overall understanding of the Company's financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. Investors are encouraged to review the reconciliation of the historical non-GAAP financial measures to its most directly comparable GAAP financial measures. As non-GAAP financial measures have material limitations as analytical metrics and may not be calculated in the same manner by all companies, they may not be comparable to other similarly titled measures used by other companies. In light of the foregoing limitations, you should not consider non-GAAP financial measures as a substitute for, or superior to, such metrics in accordance with US GAAP. Reconciliations of Non-GAAP Results Reconciliations of Non-GAAP net loss (All amounts in thousands, except share and per share data or otherwise stated) For the years ended December 31, December 31, December 31, 2021 2022 2022 RMB RMB US$ Net loss (120,087) (103,598) (15,019) Less: Change in fair value of convertible debts 9,073 (144) (21) Stock based compensation expense 34,167 14,924 2,164 Non-GAAP net loss (76,847) (88,818) (12,876)
SPRING, Texas, April 28, 2023 /PRNewswire/ -- In 2022, industry leaders ExxonMobil, Cyclyx International, Sealed Air, and Ahold Delhaize USA announced their intention to be the first in the United States to successfully launch a circular food packaging proof of concept leveraging advanced recycling. During a successful demo, plastic waste was collected from grocery stores, diverting it from landfills. Leveraging ExxonMobil's Exxtend™ technology for advanced recycling, which breaks the plastic waste into its molecular building blocks and attributes the certified-circular share via mass balance accounting, the plastic waste was converted to new food-grade packaging. This collaboration demonstrated that creating a circular economy is achievable with value chain collaboration. Following a viable test, the process is now being evaluated for scale. Circular solution for food packaging waste was first of its kind in the U.S. Flexible plastic waste from the food supply chain was recycled and attributed to ISCC PLUS certified-circular polymers used for new food-grade packaging First announced in April 2022, the project is now being evaluated for scalability Creating a circular economy for food contact plastic packaging in applications where there are strict safety and performance requirements is a difficult challenge facing the industry. "This project helps demonstrate how Exxtend technology can widen the range of plastic materials that can be recycled while delivering certified-circular polymers with the critical performance attributes of virgin plastic," said Dan Moore, vice president, Polyethylene, ExxonMobil. "Advanced recycling is making the impossible possible and is an important enabler to support a circular economy." Ahold Delhaize USA brand Food Lion supported the initial pilot, collecting plastic waste for recycling at select store locations. With more than 1,100 stores across 10 states, Food Lion is one of the five brands that comprise the Ahold Delhaize USA network – the largest grocery retail group on the East Coast and the fourth largest in the nation. "Across Ahold Delhaize USA companies, we have ambitious goals around recyclable and reusable packaging," said Adam Springer, manager, Product Sustainability, Ahold Delhaize USA. "Based on the initial pilot, we're optimistic about being able to leverage this process at additional scale and look forward to exploring it further as part of this collaboration." Cyclyx, a joint venture between Agilyx Corporation and ExxonMobil, was responsible for sorting and pre-processing the waste packaging materials collected from the Food Lion stores, before delivering them to ExxonMobil's Baytown, Texas facility. "The interface between the Food Lion stores and the Baytown facility was critical and required an innovative approach to feedstock management," said Joe Vaillancourt, CEO, Cyclyx. "Part of our process is to identify the chemical composition of the waste plastics we receive. This allows us to create custom blends of post-use plastic feedstock that are tailored to the specifications required for advanced recycling." At the Baytown facility, Exxtend technology for advanced recycling is used to recycle the valuable end of life plastics and attribute them via mass balance accounting to certified-circular polymers. "The technology provides a reliable source to attribute to high-performance, certified-circular polymers," Moore said. "The resulting polymers, such as Exceed™ S, Exceed™ XP, Exceed™ and Enable™ performance polyethylene (PE), have the characteristics of virgin resins, which is critical for food-grade packaging." Sealed Air, which is leading the packaging industry by designing and creating high-performance packaging materials that can be remade, converts the certified-circular PE resins into food-grade flexible film that is used, in the case of this proof of concept, to package select Nature's Promise fresh poultry. The packaging then returns to stores used on products purchased by customers, demonstrating an example of the circular economy. "By collaborating with suppliers and customers, we were able to identify, design, and commercialize an innovative flexible packaging solution which supports circularity," said Ron Cotterman, vice president, Global Corporate Affairs, Sealed Air. Leveraging ExxonMobil's existing manufacturing assets, Exxtend technology can be rapidly scaled to process a wide range of plastic waste. To help meet the growing market demand for certified-circular plastics, ExxonMobil plans to increase its annual advanced recycling capacity to 500,000 metric tons, or approximately 1 billion pounds, by year-end 2026 across multiple sites globally. ExxonMobil, Cyclyx, Sealed Air, and Ahold Delhaize USA demo advanced recycling for plastic waste Video - https://mma.prnasia.com/media2/2063652/ExxonMobil_ARP_Case_Study_Video_.mp4
HANGZHOU, China, April 18, 2023 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced that it has entered into a definitive agreement with an institutional investor (the "Investor") providing for the issuance of 2,258,888 ordinary shares, at a purchase price of $3.10 per share, in a registered direct offering for aggregate gross proceeds of approximately $7 million. Jo-Jo Drugstores also agreed to issue to the Investor registered warrants to purchase up to 4,517,776 ordinary shares. The warrants will have a term of five years, be exercisable immediately at an exercise price of $3.10 per share. The closing of the sale of the securities is expected to occur on or about April 20, 2023, subject to satisfaction of customary closing conditions. Jo-Jo Drugstores intends to use the net proceeds from the offering for general corporate purposes and working capital. Maxim Group LLC ("Maxim") is acting as the sole placement agent in connection with this offering. The ordinary shares and warrants described above are being offered pursuant to a "shelf" registration statement on Form F-3 (File No. 333-259692), which was declared effective by the United States Securities and Exchange Commission (the "SEC") on December 19, 2022. The ordinary shares and warrants described above may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement related to the offering will be filed with the SEC and available on the SEC's website at http://www.sec.gov. Copies of the prospectus supplements relating to the offering may be obtained, when available, by contacting: Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, by telephone: at (212) 895-3500. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About China Jo-Jo Drugstores, Inc. China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website. Forward-Looking Statements This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission. For more information, please contact: Company Contact: Frank ZhaoChief Financial Officer+86-571-88077108frank.zhao@jojodrugstores.com Investor Relations Contact: Tina XiaoAscent Investor Relations LLC+1-917-609-0333tina.xiao@ascent-ir.com
Based on a global survey of consumers and loyalty program managers, the report highlights opportunities for grocers and retailers to maximize customer engagement using their loyalty programs LONDON, April 18, 2023 /PRNewswire/ -- Rising inflation, a continuing cost-of-living crisis and evolving consumer expectations and behaviors are presenting retailers with both significant challenges and new opportunities, according to a new loyalty survey report from Eagle Eye, a global digital marketing technology company that helps retail and hospitality companies build more personalized relationships with their customers. The report, based on a survey of over 1,300 consumers and nearly 200 loyalty program managers in North America, Asia, Australia and the UK, examines what consumers look for in a loyalty program, what brands are currently investing in and what retailers should be focused on to engage shoppers. Among the report's overarching findings are three areas of opportunity for retailers to engage customers, using their loyalty programs to improve the experience and keep shoppers coming back: advanced personalization, Marketing in the Moment and gamification. "This is an uncertain environment for retailers, but consumers are also primed to appreciate the value of loyalty," said Tim Mason, CEO of Eagle Eye. "Grocery retailers are uniquely positioned to use their loyalty programs to deliver the savings their customers demand and the experiences they've come to expect." Key findings highlight the value of grocery loyalty programs The report, Grocery's Great Loyalty Opportunity, reveals that 58% of consumers are eating and drinking out less as a direct response to inflationary pressures, highlighting the opportunity for grocery retailers to engage with their customers more effectively to reap the benefits of increased grocery spending. Other report findings reveal that: 84% of consumers believe personalized recommendations will help them save at the shelf 71% of consumers would either consider buying a product or find the information helpful if they received a promotion or offer while shopping in a store 66% of consumers would participate in games, contests or challenges through a company's loyalty program 64% of consumers are buying more items on sale 69% of consumers state "value" as being the top benefit they want from a loyalty program 54% of loyalty program managers said they plan to make it easier to earn and redeem points through the loyalty program in the next 3-6 months These data points and others in the report illustrate why retailers should prioritize creating a grocery loyalty program that gives consumers what they want: value and personalized experiences. Retailers that can successfully use personalization to make their customers' lives easier, execute one-to-one communications at precisely the right moment for the right individual and incorporate gamified interactions that improve the overarching experience will be those that will win their customers' loyalty, even in these most challenging of times. Download Eagle Eye's global loyalty survey report, Grocery's Great Loyalty Opportunity, here. For more information about the company's survey report or to schedule an interview with Eagle Eye CEO Tim Mason, please contact Vanessa Horwell at vhorwell@thinkinkpr.com. About Eagle EyeEagle Eye is a leading SaaS technology company transforming marketing by creating digital connections that enable personalised performance marketing in real time through coupons, loyalty, apps, subscriptions and gift services. Eagle Eye AIR enables the secure issuance and redemption of digital offers and rewards at scale across multiple channels, enabling a single customer view. We create a network between merchants, brands and audiences to enable customer acquisition, interaction and retention at a lower cost while driving marketing innovation. The Company's current customer base comprises leading names in UK Grocery, Retail, Leisure and Food & Beverage sectors, including Asda, Tesco, Waitrose and John Lewis & Partners, Virgin Red, JD Sports, Pret A Manger, Mitchells & Butlers, Pizza Express; in North America, Loblaws, Shoppers Drug Mart, Southeastern Grocers and Staples US Retail, and in Australia & New Zealand, Woolworths Group and The Warehouse Group. Visit www.eagleeye.com for more information.
TIANJIN, China, April 14, 2023 /PRNewswire/ -- According to a report by global market intelligence company Mintel[1], the retail sales of frozen and chilled ready meals in China were expected to reach ¥243.8 billion (approximately US$35.4 billion or S$47.0 billion) in 2022, with an accelerated growth of 12.8% from 9.5% in 2021. This has led leading provider of food solutions and gateway services SATS Ltd. ("SATS") to strengthen its presence in China, with opening of a 21,553.13m2 central kitchen in Tianjin today. Opening ceremony of SATS Tianjin central kitchen SATS has built its reputation over the last 50 years, with customers ranging from leading air carriers, supermarkets, quick service restaurants and coffee chains to institutions such as corporates and schools. Under its "twin-engine" growth strategy, the Singapore-headquartered company is committed to strengthening its competencies on home soil and replicating them overseas as it expands globally. This includes China, where SATS has been operating for the last 30 years including in the food space, supported by central kitchens in Beijing, Kunshan and Nanjing as well as a product development and experience centre in Shanghai – all connected to the company's network of capabilities including the SATS Global Innovation Hub and upcoming SATS Food Hub. The ¥219 million (equivalent to approximately US$31.83 million or S$42.23 million) investment in the latest central kitchen in Tianjin is a move to adapt to customers' evolving needs, by deploying the latest automation and technology as well as harnessing SATS' high food safety standards, international culinary expertise, and domain knowledge in food technology and research and development. The facility is strategically located between Beijing and Tianjin, enabling SATS to offer a wide variety of high quality meals to customers not just in the northern region but also the rest of China and beyond. Kerry Mok, President and Chief Executive Officer of SATS Ltd. said, "Throughout our 50 years feeding and connecting communities, SATS has built a reputation for our quality and safety standards. On the food solutions front, our meals are always prepared in compliance with the most stringent safety regulations, and we are constantly on the lookout for technological innovations to help increase productivity and improve food quality. Through the SATS Tianjin central kitchen, we hope to leverage our know-how and capabilities to bring authentic global flavours to the Chinese communities." [1] Mintel Reports China, Ready Meals, 2022.
A12 藝術空間
Supermarkets
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)